PharmaCompass: Nitrosamine impurities can be avoided by careful selection of raw materials and processing conditions.

Since 2018, several drug products have been found to contain unacceptable levels of nitrosamines. In this PharmaCompass article, Recro experts address the steps pharmaceutical companies need to take to assess and mitigate risks from nitrosamine impurities.

Want to know more?

Read the Article

Back to Thought Leadership